NatureCellLtd Valuation

Is A007390 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A007390 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A007390's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A007390's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A007390?

Key metric: As A007390 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A007390. This is calculated by dividing A007390's market cap by their current book value.
What is A007390's PB Ratio?
PB Ratio	26.3x
Book	₩64.12b
Market Cap	₩1.69t

A007390 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	58.3x
Enterprise Value/EBITDA	-587.4x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A007390's PB Ratio compare to its peers?

The above table shows the PB ratio for A007390 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	240x
A006280 GC Biopharma	1.2x	104.4%	₩1.5t
A298380 ABL Bio	950.7x	54.8%	₩1.3t
A214450 PharmaResearch	4.3x	25.3%	₩2.1t
A145020 Hugel	3.9x	20.7%	₩3.0t
A007390 NatureCellLtd	26.3x	n/a	₩1.7t

Price-To-Book vs Peers: A007390 is good value based on its Price-To-Book Ratio (26.3x) compared to the peer average (240x).

Price to Book Ratio vs Industry

How does A007390's PB Ratio compare vs other companies in the KR Biotechs Industry?

4 Companies	Price / Book	Estimated Growth	Market Cap
A377740 BioNote	0.3x	n/a	US$343.44m
A950210 Prestige BioPharma	0.4x	n/a	US$131.24m
A109960 AP Healthcare	0.3x	n/a	US$70.00m
A950220 NeoImmuneTech	0.4x	n/a	US$17.13m

No more companies available in this PB range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: A007390 is expensive based on its Price-To-Book Ratio (26.3x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A007390's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A007390 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	26.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A007390's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩53.0b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,270.00

-2.5%

n/a

Medy-Tox

₩856.2b

Operates as a biopharmaceutical company in South Korea.

A086900

₩127,200.00

1.0%

-42.2%

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩277,500.00

1.3%

76.0%